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Abstract: Non-metastatic castration-resistant prostate cancer (nmCRPC) is defined by a progressively
rising prostate-specific antigen level, despite a castrate level of testosterone, in the absence of obvious
radiologic evidence of metastatic disease on conventional imaging modalities. As a significant
proportion of patients with nmCRPC develop metastatic diseases, the therapeutic goals of physicians
for these patients are to delay metastasis development, preserve quality of life, and increase overall
survival (OS). Since 2018, the treatment of nmCRPC has changed dramatically with the introduction of
second-generation androgen receptor inhibitors, such as enzalutamide (ENZA), apalutamide (APA),
and darolutamide (DARO). These drugs demonstrated substantial improvements in metastasis-free
survival (MFS) and OS in phase III randomized clinical trials. In addition, these drugs have an
excellent safety profile, preserve quality of life, and can delay disease-related symptoms. A recently
published indirect meta-analysis reported that APA and ENZA showed better findings in MFS and
that DARO had relatively fewer adverse effects. However, in the absence of a direct comparison,
careful interpretation is required. Thus, APA, ENZA, and DARO should be considered the new
standard drugs for treating nmCRPC.
Keywords: second-generation androgen receptor inhibitors; non-metastatic castration-resistant
prostate cancer; apalutamide; enzalutamide; darolutamide
1. Introduction
Androgen deprivation therapy (ADT) [1], encompassing surgical and chemical cas-
tration [2], has shown significant clinical benefits in the management of advanced and
metastatic prostate cancer [3]. Most prostate cancers initially respond to ADT but even-
tually develop resistance, transforming from castration-sensitive to castration-resistant
prostate cancer (CRPC) [4]. Non-metastatic castration-resistant prostate cancer (nmCRPC)
is a unique disease condition regarded as a “bridge” to metastatic CRPC (mCRPC). Contin-
uous ADT is advised for nmCRPC until it progresses to metastatic disease [5]. Imaging
studies have revealed the incidence of metastasis despite continuous ADT in patients with
a median metastasis-free survival (MFS) of approximately 15 months [6,7]. First-generation
androgen receptor inhibitors (ARi), such as bicalutamide or flutamide, and antiandrogen
withdrawal syndrome therapy are conventionally used to treat nmCRPC but without any
significant survival benefit [8–11]. In recent years, the development of and conduction of
clinical trials for novel second-generation ARi have changed the treatment landscape for
nmCRPC. Second-generation ARi bind to androgen receptors with a 7- to 10-fold greater
affinity than do first-generation ARi [12–14]. In addition, the formers bind directly to the
ligand-binding domain of the androgen receptor, inhibit its nuclear translocation, inhibit
DNA binding, and impede androgen receptor-mediated transcription [15,16]. Between
2018 and 2019, the Food and Drug Administration (FDA) approved three second-generation
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ARi for nmCRPC [17]. These drugs are orally administered and their characteristics are
summarized in Table 1. They raised new hopes of prolonging overall survival (OS) of
patients with nmCRPC and changed the treatment paradigm for nmCRPC. In this review,
we discuss and compare three second-generation ARi that have undergone large-scale
phase 3 randomized clinical trials (RCTs).
Table 1. Comparison of basic characteristics for second-generation AR inhibitors.
Apalutamide [18] Enzalutamide [19] Darolutamide [20]
Brand name Erleada Xtandi Nubeqa
Dose/form 60 mg/tablet 40 mg/capsule 300 mg/film-coated tablet
Total daily dosage 240 mg (once per day) 160 mg (once per day) 600 mg (twice per day)
Route of administration Oral administration Oral administration Oral administration
Approved indication nmCRPC, mCSPC nmCRPC, mCSPC, mCRPC nmCRPC
Chemical structure
Biomedicines 2021, 9, x FOR PEER REVIEW 2 of 14 
 
tor-mediated transcription [15,16]. Between 2018 and 2019, the Food and Drug Admin-
istration (FDA) approved three second-generation ARi for nmCRPC [17]. These drugs are 
orally administered and their characteristics are summarized in Table 1. They raised new 
hopes of prolonging overall survival (OS) of patients with nmCRPC and changed the 
treatment paradigm for nmCRPC. In this review, we discuss and compare three sec-
ond-generation ARi that have undergone large-scale phase 3 randomized clinical trials 
(RCTs). 
Table 1. Comparison of basic characteristics for second-generation AR inhibitors. 
Apalutamide [18] Enzalutamide [19] Darolutamide [20] 
Brand name Erleada Xtandi Nubeqa 
Dose/form 60 mg/tablet 40 mg/capsule 300 mg/film-coated tablet 
Total daily dosage  240 mg (once per day) 160 mg (once per day) 600 mg (twice per day) 
Route of administration Oral administration Oral administration Oral administration 




Bioavailability 100% [21] 
Rats: 89.7% [22]; humans: unknown 





Carboxylic acid derivative 
metabolite (inactive) 
Ketodarolutamide 




Urine: 71.0%  
Bile: 13.6% 





Yes Yes Negligible 
Mechanism of action 
for AR inhibition 
It binds to the ligand-binding 
domain of the androgen receptor, 
blocks androgen-receptor nuclear 
translocation, inhibits DNA 
binding, and obstructs androgen 
receptor-mediated transcription. 
It prevents the translocation of the 
AR from the cytoplasm to the 
nucleus. Within the nucleus, it 
inhibits AR binding to 
chromosomal DNA, which prevents 
further transcription of tumor 
genes. 
It competitively inhibits androgen 
binding, AR nuclear translocation, 
and AR-mediated transcription.  
A major metabolite, 
keto-darolutamide, exhibited 
similar in vitro activity to 
darolutamide. 
AR, androgen receptor; nmCRPC, non-metastatic castration-resistant prostate cancer; mCRPC, metastatic castra-
tion-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer. 
2. Definition of nmCRPC 
To assist in clinical decision making, six index patients were described in the 
American Urology Association guideline to represent the most common clinical scenari-
os; the disease condition of the first index patient was defined as asymptomatic, 
nmCRPC [25]. The National Comprehensive Cancer Network guidelines define 
nmCRPC as CRPC lacking evidence of metastases on conventional imaging [26]. More 
specifically, the Prostate Cancer Clinical Trials Working Group 3 defined nmCRPC as a 
progressively rising prostate-specific antigen (PSA) level, namely a 25% PSA increase 
from nadir (starting PSA ≥ 1.0 ng/mL), with a minimum increase of 2 ng/mL despite a 
i e i i es , ,    I   f  
 
i  i i  , .    ,     i
i i     i  i   .    
ll  i i   i  i i   i  i  l  .  i   
  l i  ll i l   i  i      
 i   .  i  i ,  i     
i  i    l l    i  li i l i l  
. 
l  . i  f i  t i ti  f  - ti   i i it . 
l t i  [ ] l t i  [ ] l t i  [ ] 
  l  t i  
/f   /t l t  / l   /fil - t  t l t 
t l il      (   )   (   )   (t i   ) 
t  f i i t ti  l i i t ti  l i i t ti  l i i t ti  
 i i ti  ,  , ,   
i l t t  
 
  
i il ilit   [ ] 
t : .  [ ]; :  
( t l t . ;    
f  ti ) 
 
t lit  - t l l t i  
- t l l t i  ( ti ) 
li  i  i ti  
t lit  (i ti ) 
t l t i  
lf-lif    ( t t  t t ) .   (  . .  )   [ ] 
ti  
i :  
:  
i : .   
il : .  
: .  [ ] 
i : .  
: .  
l i  i  
t ti  
  li i l  
i  f ti  
f   i i iti  
It i  t  t  li - i i  
i  f t   t , 
l  - t  l  
t l ti , i i it   
i i ,  t t   
t - i t  t i ti . 
It t  t  t l ti  f t  
 f  t  t l  t  t  
l . it i  t  l , it 
i i it   i i  t  
l , i  t  
f t  t i ti  f t  
. 
It titi l  i i it   
i i ,  l  t l ti , 
 - i t  t i ti .  
 j  t lit , 
t - l t i , i it  
i il  i  it  ti it  t  
l t i . 
,  t ; , - t t ti  t ti - i t t t t  ; , t t ti  t -
ti - i t t t t  ; , t t ti  t ti - iti  t t  . 
.    
 i  i  li i l i i  i , i  i  i   i  i   
i  l  i i  i li       li i l i
;  i  i i    i  i  i   i   i , 
 .  i l i    i li  i  
   l i  i     i l i i  .  
i i ll ,    li i l i l  i    i     
i l  i i  i i  i   l l, l     i  
 i  i    .  , i   i i  i     i   
Biomedicines 021, 9, x FOR PEE  REVIEW 2 of 14 
 
tor-mediated transcription [15,16]. Between 2018 and 2019, the F od and Drug Admin-
istration (FDA) a proved three second-generation ARi for nmCRPC [17]. These drugs are 
orally administered and their characteristics are su marized in Table 1. They raised new 
hopes of pr longing overall sur ival (OS) of patients with nmCRPC and changed the 
treatment paradigm for nmCRPC. In this review, we discuss and compare three sec-
ond-generation ARi that have undergone large-scale phase 3 randomized clinical trials 
(RCTs). 
Table 1. Comparison of basi  ch racteristics for second-generation AR inh bitors. 
Apalutamide [18] Enzalutamide [19] Darolutamide [20] 
Brand name Erleada Xtandi Nubeqa 
Dose/form 60 mg/t blet 40 mg/capsule 300 mg/film-coated tablet 
Total daily dosage  240 mg (once per day) 160 mg (once per day) 600 mg (twice per day) 
Route of adm nistration Oral adm nistration Oral adm nistration Oral adm nistration 




Bioavailability 100% [21] 
Rats: 89.7% [22]; humans: unknown 





Carboxylic aci  derivative 
metabolite (inactive) 
Ketodarolutamide 
Half-life 3–4 days (at steady s ate) 5.8 days (range 2.8–10.2 days) 16–20 h [23] 
Excretion 
Urine: 65% 
F ces: 24% 
Urine: 71.0%  
Bile: 13.6% 
F ces: 0.39% [24] 
Urine: 63.4% 
F ces: 32.4% 
Blood–brain barrier 
penetration 
Yes Yes Negl gible 
Mechanism of action 
for AR inh bition 
It binds to the ligand-binding 
domain of the androgen r ceptor, 
blocks androgen-r ceptor nuclear 
translocation, inh bits DNA 
binding, and obstructs androgen 
r ceptor-mediated transcription. 
It prevents the translocation of the 
AR from the cytoplasm to the 
nucleus. Within the nucleus, it 
inh bits AR binding to 
chrom somal DNA, which prevents 
further transcription of tumor 
genes. 
It competitively inh bits androgen 
binding, AR nuclear translocation, 
and AR-mediated transcription.  
A major metabolite, 
keto-darolutamide, exh bited 
similar in vitro act vity to 
darolutamide. 
AR, androgen r ceptor; nmCRPC, non-metas atic castration-re istant pros ate cancer; mCRPC, metas atic castra-
tion-re istant pros ate cancer; mCSPC, metas ati  castration-sensitive pros ate cancer. 
2. Defin tion of nmCRPC 
To as ist in clinical dec sion making, six index patients w re described in the 
American Ur logy Association guideline to represen  the most co mon clinical scenari-
os; the disease condition of the first index patient was defined as asymptomatic, 
nmCRPC [25]. The National Comprehensive Cancer Network guidelines define 
nmCRPC as CRPC lacking evidence of metastases on conventional imaging [26]. More 
spec fically, the Prostate Cancer Clinical Trials Working Group 3 defined nmCRPC as a 
progressively r sing pros ate-spec fic antigen (PSA) level, namely a 25% PSA increase 
from nadir (starting PSA ≥ 1.0 ng/mL), with a minimum increase of 2 ng/mL despite a 
Bioavailability 100% [21]
Rats: 89.7% [22]; huma s:
unknown









Half-life 3–4 days (at steady state) 5.8 days (range 2.8–10.2 days) 16–20 h [23]







penetration Yes Yes Negligible
Mechanism of action
for AR inhibiti n
It binds to the ligand-binding
domain of the androgen
receptor, blocks
androgen-receptor nuclear




It prevents the translocation of
the AR from the cytoplasm to
the nucleus. Within the nucleus,
it inhibits AR binding to
chromosomal DNA, which
prevents further transcription of
tumor genes.
It competitively inhibits
androgen binding, AR nuclear
translocatio , and AR-mediated
transcription.
A ajor me abolite,
keto-darolutamide, exhibited
similar in vitro activity to
darolutamide.
AR, androgen receptor; nmCRPC, non-metast tic castration-resistant pr state cancer; mCRPC, m tastatic castration-resi tant prostate
cancer; mCSPC, metastatic castration-sensitive prostate cancer.
2. Definition of nmCRPC
To assist in clinical decision making, six index patients were described in the American
Urology Association guideline to represent the most common clinical scenarios; the disease
condition of the first index patient was defined as asymptomatic, nmCRPC [25]. The
National Comprehensive Cancer Network guidelines define nmCRPC as CRPC lacking
evidence of metastases on conventional imaging [26]. More specifically, the Prostate Cancer
Clinical Trials Working Group 3 defined nmCRPC as a progressively rising prostate-specific
antigen (PSA) level, namely a 25% PSA increase from nadir (starting PSA ≥ 1.0 ng/mL),
with a minimum increase of 2 ng/mL despite a castrate level of testosterone (<50 ng/dL) in
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the absence of obvious radiologic evidence of metastatic disease on conventional imaging
modalities [27].
A substantial percentage of patients with nmCRPC develop metastatic lesions. Smith
et al. reported that 46% of men with nmCRPC developed metastasis within 2 years [5,28].
Recently, Moreira et al. also reported that among nmCRPC patients, nearly 60% developed
metastatic disease during the first 5 years, with most of the cases of metastasis occurring
within the first 3 years [29]. In nmCRPC, baseline PSA level, PSA velocity, and PSA
doubling time (PSADT) have been associated with time to bone metastases, MFS, and
OS [30–32]. Therefore, the therapeutic goals of physicians in these patients are to delay
metastasis development, preserve quality of life (QOL), and increase OS.
3. Phase III Clinical Trials Assessing the Effect of Second-Generation ARi
for nmCRPC
3.1. SPARTAN (Apalutamide)
On 14 February 2018, the FDA approved apalutamide (APA; Erleada™, janssen Phar-
maceuticals, Inc., Beerse, Belgium) for patients with nmCRPC. SPARTAN (NCT01946204)
was a phase III, randomized, double-blind, placebo-controlled, multicenter study designed
to evaluate the efficacy and safety of APA (240 mg per day) compared to those of placebo in
1207 patients (806 in the APA group and 401 in the placebo group) with high-risk nmCRPC
(patients whose PSADT was ≤10 months) [7,33]. This study allowed the enrolment of
patients with asymptomatic pelvic lymph node enlargement. Continuous ADT with a
GnRH analog or surgical castration was required among the sample. The primary endpoint
was MFS, which was defined as the time from randomization to the first detection of distant
metastasis on imaging (as assessed by a blinded independent central review) or death from
any cause, whichever occurred first.
The planned primary analysis was performed after 378 events (distant metastasis or
death) had occurred [7]. Median MFS was 40.5 months in the APA group and 16.2 months
in the placebo group (hazard ratio (HR) for metastasis or death, 0.28; 95% confidence
interval (CI), 0.23–0.35; p < 0.001). The APA group showed improvements over the placebo
group in all secondary endpoints, including time to metastasis (HR, 0.27; 95% CI, 0.22–0.34;
p < 0.001) and progression-free survival (HR, 0.29; 95% CI, 0.24–0.36; p < 0.001). Time to
symptomatic progression was significantly longer with APA than with placebo (HR, 0.45;
95% CI, 0.32–0.63; p < 0.001).
There was no statistically significant difference in the analysis of OS in the initial
report (HR, 0.70; 95% CI, 0.47 to 1.04; p < 0.07) [7]. Thereafter, the final analysis for OS was
reported when the median follow-up was 52 months [33]. By the time of this analysis, 428
deaths had occurred. After the primary endpoint analysis was met, the study was blinded.
There were 76 (19%) patients in the crossover group who received APA after placebo. The
median treatment duration was 32.9 months in the APA group, 11.5 months in the placebo
group, and 26.1 months with APA in the crossover group. Subsequent life-prolonging
therapy was received by 371 (46%) patients in the APA group and 338 (84%) patients in the
placebo group, including crossover group patients. The median OS was 73.9 months in the
APA group and 59.9 months in the placebo group (HR, 0.78; 95% CI, 0.64–0.96; p = 0.016).
In addition, APA was associated with a significant prolongation of time to first cytotoxic
chemotherapy (median not reached in either group; HR, 0.63; 95% CI, 0.49–0.81; p = 0.0002).
According to the final analysis, discontinuation rate due to progressive disease was
43% in the APA group and 74% in the placebo group. This was the most common cause
of drug discontinuation. The rate of adverse events leading to discontinuation of the trial
regimen was 15% (120/803) in the APA group and 7.3% (29/398) in the placebo group.
Adverse effects (AEs) of grade 3 or 4 occurred in 56% (449/803) and 36% (145/398) of
the patients in the APA and placebo groups, respectively. The AEs that occurred in more
than 15% of patients in the APA group (vs. in placebo group) were as follows: fatigue
(33% vs. 21%), hypertension (HTN) (28% vs. 21%), diarrhea (23% vs. 15%), fall (22% vs.
9.5%), nausea (20% vs. 16%), arthralgia (20% vs. 8.3%), weight loss (20% vs. 6.5%), back
pain (18% vs. 15%), and hot flushes (15% vs. 8.5%).
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3.2. PROSPER (Enzalutamide)
On 13 July 2018, the FDA approved enzalutamide (ENZA; Xtandi, Astellas Pharma US,
Inc., Tokyo, Japan) for patients with nmCRPC. PROSPER (NCT02003924) was a phase III,
randomized, double-blind, placebo-controlled (in a 2:1 ratio), multicenter study designed
to evaluate the efficacy and safety of ENZA (160 mg per day) compared to those of placebo
in 1401 patients with high-risk nmCRPC (patients whose PSADT was ≤10 months) [6,34].
This study included 933 patients in the ENZA group and 468 patients in the placebo
group. Patients with suspected brain metastases, active leptomeningeal disease, a history
of seizures, or a condition that may confer a predisposition to seizures were excluded.
The primary endpoint was MFS, defined as either the time from randomization to
radiographic progression, as determined by a central reviewer at any time, or as the
time to death from any cause during the period from randomization to 112 days after
the discontinuation of the trial regimen without evidence of radiographic progression,
whichever occurred first. In the primary analysis, a total of 219/933 patients (23%) in
the ENZA group had metastasis or died as compared with 228/468 (49%) patients in the
placebo group. The median MFS was 36.6 months in the ENZA group versus 14.7 months
in the placebo group. A statistically significant and clinically meaningful improvement in
MFS (HR, 0.29; 95% CI, 0.24–0.35; p < 0.001) was seen in the ENZA group. PSA progression-
free survival was 37.2 months in the ENZA group and 3.9 months in the placebo group (HR,
0.07; 95% CI, 0.05–0.08; p < 0.001). The time to the first use of a subsequent antineoplastic
therapy was longer with ENZA treatment than with placebo (39.6 months vs. 17.7 months;
HR, 0.21; 95% CI, 0.17–0.26; p < 0.001). Similar to the SPARTAN study, the complete analysis
of the OS was not released in the initial report. In subsequent reports [34], ENZA-treated
patients showed a significant 27% decreased risk of death than placebo recipients did. The
median follow-up period was 48 months, as of October 15, 2019. There were 466 deaths, of
which 288/930 (30.9%) occurred in the ENZA group and 178/465 (38.0%) in the placebo
group. A total of 87 patients received ENZA in the crossover group. ENZA significantly
prolonged OS compared to placebo (HR, 0.73; 95% CI 0.61–0.89; p = 0.001). The median
OS was 67.0 months (95% confidence interval (CI), 64.0 not reached (NR)) in the ENZA
group and 56.3 months (95% CI, 54.4–63.0) in the placebo group. Subsequent antineoplastic
therapies were initiated after treatment discontinuation in 310 (33%) patients in the ENZA
group and 303 (65%) patients in the placebo group. Median duration of treatment was
33.9 months vs. 14.2 months with ENZA vs. placebo, respectively.
Based on the final analysis, grade ≥ 3 AEs were reported by 446/930 (48%) patients in
the ENZA group vs. 126/465 (27%) patients in the placebo group. The rate of AEs leading
to discontinuation of the trial regimen was 158/930 (17%) in the ENZA group and 41/465
(9%) in the placebo group. The AEs that occurred in more than 15% of patients in the
ENZA group (vs. placebo group) were as follows: fatigue (46% vs. 22%); musculoskeletal
events, including back pain, arthralgia, myalgia, musculoskeletal pain, pain in the extrem-
ities, musculoskeletal stiffness, muscular weakness, and muscle spasms (34% vs. 23%);
hypertension (HTN) (18% vs. 6%); fall (18% vs. 5%); and fracture (18% vs. 6%).
3.3. ARAMIS (Darolutamide)
On 30 July 2019, the FDA approved darolutamide (DARO; Nubeqa, Bayer Health-
Care Pharmaceuticals, Inc., Whippany, Hanover, NJ, USA) for nmCRPC treatment [35,36].
ARAMIS (NCT02200614) is the largest phase III randomized, double-blind, placebo-
controlled trial conducted for nmCRPC to date. It included patients with a PSADT of
≤10 months and pelvic lymph nodes <2 cm below the aortic bifurcation. In this study,
patients with previous seizures or conditions predisposing to seizures were permitted in
both groups. This RCT assigned 1509 men, at a 2:1 ratio, to receive DARO (600 mg twice
daily) (955 patients) or placebo (554 patients) while continuing to receive ADT. The final
analysis was scheduled to be published after approximately 240 deaths occurred. However,
the primary endpoint, MFS, was better in the DARO group, and the trial was changed
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to an unblinded study after only 136 deaths. OS and all other secondary endpoints were
evaluated thereafter. Good OS was seen in the DARO group.
The median follow-up time was 29.0 months. At the time of data unblinding, all
170 patients who were still receiving the placebo started receiving DARO. One hundred
and thirty-three patients who had discontinued placebo before data unblinding received at
least one other life-prolonging therapy.
The MFS results from the ARAMIS trial are presented. In total, 221/955 patients
(23%) in the DARO group developed metastasis or died, as compared with 216/554 (39%)
patients in the placebo group. Participants treated with DARO achieved a median MFS
of 40.4 months (95% CI, 34.3 NR), more than double the 18.4 months (95% CI, 15.5–22.3)
achieved by those given placebo. This was a statistically strong significant finding (HR, 0.41;
95% CI, 0.34–0.5; p < 0.001). The OS rate at 3 years was 83% (95% CI, 80–86) in the DARO
group and 77% (95% CI, 72–81) in the placebo group. The risk of death was significantly
lower in the DARO group than in the placebo group (HR, 0.69; 95% CI, 0.53–0.88; p = 0.003).
DARO was also associated with a significant benefit with respect to all other secondary
endpoints, including the time to pain progression (HR, 0.65; 95% CI, 0.53–0.79; p < 0.001)
that was extended by 14.9 months in the DARO group compared to that in the placebo
group. The time to the first symptomatic skeletal event (HR, 0.48; 95% CI, 0.29–0.82;
p < 0.001) and the time to the first use of cytotoxic chemotherapy were reported (HR, 0.58;
95% CI, 0.44–0.76; p < 0.001).
Grade 3–4 AEs were reported by 10.9% (104/954) of the patients in the DARO group
vs. 6.5% (36/554) of the patients in the placebo group. No AEs were seen in more than
15% of the DARO group participants. The most common AE was fatigue (13% vs. 8%).
Therefore, the trial reported that the incidence of AE after treatment initiation was similar
between the two groups. In addition, the discontinuation rates were comparable between
the placebo (8.9%) and DARO (8.7%) groups.
We summarized and presented the data in three studies in Tables 2 and 3.
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HR 0.07
(95% CI 0.06–0.09); p < 0.0001 HR 0.07 (95% CI 0.05–0.08); p < 0.001
HR 0.13
(95% CI 0.11–0.16); p < 0.001
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Time to initiation of
cytotoxic chemotherapy
HR 0.63
(95% CI 0.49–0.81); p = 0.0002 NR
HR 0.58
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Time to initiation of
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therapy
NR HR 0.29(95% CI 0.25–0.34); p < 0.001
HR 0.36
(95% CI 0.27–0.48); p < 0.001
APA, apalutamide; CI, confidence interval; DARO, darolutamide; ENZA, enzalutamide; HR, hazard ratio; MFS, metastasis-free survival, NR,
not reported; OS, overall survival; PBO, placebo; PFS, progression-free survival; PSA, prostate-specific antigen; PSADT, PSA doubling time.








APA (n = 803) PBO (n = 398) ENZA (n = 930) PBO (n = 465) DARO (n = 954) PBO (n = 554)
Any AE 781 (97) 373 (94) 876 (94) 380 (82) 818 (85.7) 439 (79.2)
Grade 3 or 4 AE 449 (56) 145 (36) 292 (31) 109 (23) 251 (26.3) 120 (21.7)
Any serious AE 290 (36) 99 (25) 372 (40) 100 (22) 249 (26.1) 121 (21.8)
AE leading to
discontinuation 120 (15.0) 29 (7.3) 158 (17) 41 (9) 85 (8.9) 48 (8.7)
AE leading to
death 24 (3.0) 2 (0.5) 51 (5.0) 3 (1.0) 38 (4.0) 19 (3.4)
Fatigue * 265 (33) 83 (21) 424 (46) 103 (22) 126 (13.2) 46 (8.3)
Hypertension * 225 (28) 83 (21) 161 (17) 27 (6) 74 (7.8) 36 (6.5)
Falls * 177 (22) 38 (9.5) 164 (18) 25 (5) 50 (5.2) 27 (4.9
Bone fracture * 145 (18) 30 (7.5) 168 (18) 29 (6) 52 (5.5) 20 (3.6)
Arthralgia * 160 (20) 33 (8.3) 119 (13) 36 (8) 86 (9.0) 52 (9.4)
Constipation * not reported 121 (13) 39 (8) 66 (6.9) 36 (6.5)
Diarrhea * 184 (23) 60 (15) 112 (12) 47 (10) 71 (7.4) 31 (5.6)




41 (5.1) 12 (3) 73 (8) 10 (2) 19 (2.0) 10 (1.8)
Rash * 212 (26) 25 (6.3) 38 (4) 13 (3) 30 (3.1) 6 (1.1)
Seizure * 5 (0.6) 0 3 (<1) 0 2 (0.2) 1 (0.2)
AE, adverse events; APA, apalutamide; DARO, darolutamide; ENZA, enzalutamide; PBO, placebo; *, all grades of AE; data were presented
as n (%).
4. Comparison of Efficacy and Safety of Second-Generation ARi
Presently, the scope of FDA approval for the three drugs differs. APA is approved for
nmCRPC and metastatic castration-sensitive prostate cancer (mCSPC) [7,33,37,38]. ENZA
is an androgen receptor antagonist approved for all three indications: nmCRPC, mCSPC,
and mCRPC [6,34,39,40]. Finally, DARO is an androgen receptor antagonist approved only
for nmCRPC [36].
These ARi have been proven effective in phase III RCTs in patients with nmCRPC.
Many similarities exist among the SPARTAN, PROSPER, and ARAMIS trials. All partici-
pants had high-risk nmCRPC, defined by a baseline PSA level of 2 ng/mL and a PSADT
≤10 months, and the primary endpoint in each trial was MFS as assessed by computed
tomography and a bone scan of the pelvis, chest, and abdomen every 16 weeks. The three
RCTs targeted high-risk patients with nmCRPC. Nodal disease was present in patients in
all three trials. Although both the ARAMIS and SPARTAN trials permitted the enrolment
of patients with malignant nodes <2 cm in diameter located below the aortic bifurcation,
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only the SPARTAN trial set a threshold of node size <1.5 cm. All patients underwent ADT
throughout the intervention phase.
There was one difference between the participants in the three trials; patients with a
history of seizures were excluded from the PROSPER and SPARTAN trials. This is because
administration of ENZA or APA is associated with an increased risk of seizures [41–43]
due to penetration of the compound through the blood–brain barrier (BBB) and subsequent
inhibition of γ-aminobutyric acid receptors [44]. In contrast, DARO has limited penetration
through the BBB and, thus, a limited effect on mental status. This has been demonstrated
in preclinical trials of DARO [45,46]. A study showed that the penetration rate of ENZA
and APA to the BBB was more than 10 times that of DARO [47]. Therefore, DARO has been
reported to be safe in patients with a history of seizures [14], and, thus, the ARAMIS trial
did not exclude patients with a history of seizures unlike the SPARTAN and PROSPER
trials did. In the PROSPER, SPARTAN, and ARAMIS trials, the incidences of seizures in
the placebo arms were 0%, 0%, and 0.2%, respectively, whereas those in the intervention
(ENZA, APA, and DARO) arms were <1%, 0.2%, and 0.2%, respectively.
Looking at the results of the three studies, all three drugs showed better oncologic
outcomes in nm CRPC than placebo did. However, there are no direct comparative studies
between the three drugs. Therefore, it is not yet clear which drug is superior among them.
Therefore, we tried to indirectly compare the results of the three drugs based on a published
network meta-analysis of phase III RCT results [48–52].
4.1. MFS and PSA Progression-Free Survival
In the primary analyses, treatment with APA (HR, 0.28; 95% CI, 0.23–0.35; p < 0.001),
ENZA (HR, 0.29; 95% CI, 0.24–0.35; p < 0.001), or DARO (HR, 0.41; 95% CI, 0.34–0.50;
p < 0.001) than treatment with placebo as an adjunct to ADT was associated with an
approximately two-year increase in median MFS. These results suggest the superiority in
oncologic outcomes of the three drugs (APA, ENZA, and DARO) over placebo. According
to a published network meta-analysis [49–51], the SPARTAN and PROSPER trials showed
superiority over the ARAMIS trials in terms of MFS. However, there was no difference in
the indirect comparison between APA and ENZA. Although PSA progression-free survival
showed similar results, it is difficult to draw conclusions until a direct comparison is made.
In a recently published study, DARO was compared with APA and ENZA by selection
and reweighting to match the inclusion criteria and baseline characteristics of the patients;
however, no statistically significant difference was seen in the MFS [53]. Therefore, a careful
interpretation is required.
4.2. OS
In the final analyses, all RCTs showed an improvement in OS with the intervention
compared with placebo; the SPARTAN, PROSPER, and ARAMIS trials reported HRs of
0.78 (95% CI; 0.64–0.96; p = 0.016), 0.73 (95% CI; 0.61–0.89; p = 0.001), and 0.69 (95% CI;
0.53–0.88; p = 0.003), respectively. A published network meta-analyses, analyses using the
final data of each RCT, were performed by Roumiguie et al. [52]. However, current data
are insufficient to assess the significant ranking of the three drugs over placebo in terms of
OS. Unlike for MFS and PSA progression-free survival, all three studies showed similar
results for OS. Although the ARAMIS trial has not yet reported the median OS, it showed
similar OS results compared to a relatively low MFS. However, the OS may eventually
differ when the drugs are administered after cancer progression. In the three studies,
there were differences in subsequent therapy after nmCRPC progression. As for the choice
of the drug used in the subsequent therapy, the SPARTAN trial used abiraterone more
frequently than the other two did; the PROSPER trial used abiraterone and chemotherapy
at a similar rate, whereas the ARAMIS trial prescribed chemotherapy the most often. The
optimal subsequent therapy for CRPC remains controversial [54–58]. Currently, studies
on biomarkers are underway to predict treatment response and prognosis. Among the
biomarkers investigated, AR splice variant 7 (AR-V7) appears to be a promising biomarker
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for predicting the response to AR axis-targeted agents. AR-V7 is an important marker
for resistance to AR axis-targeted agents [59]. There has been no prospective study of the
AR-V7 mutation wherein secondary AR inhibitors were used. However, in this study, the
mutation was slightly more when using ENZA or abiraterone. Although AR-V7 mutation is
not an absolute criterion for drug use in patients with CRPC, it may be a factor in reducing
the effectiveness of secondary ARi [60]. De Wit et al. reported that cabazitaxel showed
better results than ENZA or abiraterone as subsequent therapy in mCRPC patients (HR,
0.64; 95% CI, 0.46–0.89; p = 0.008) [61]. Although chemotherapy cannot be considered in all
patients [62,63], additional studies on the optimal subsequent therapy in nmCRPC patients
are necessary.
4.3. Safety
The SPARTAN trial collected data on AEs at one-month intervals, whereas the PROS-
PER and ARAMIS trials collected AE-related data at four-month intervals. Compared to
the placebo group, the APA group had higher rates of fatigue, HTN, rash, weight loss,
arthralgia, and fracture, while the ENZA group had higher rates of fatigue, HTN, dizziness,
falls, and fracture. The occurrence of fatigue was higher in the DARO group than in the
placebo group.
There was an increase in HTN incidence in the SPARTAN and PROSPER intervention
groups. It is a potent inducer of CYP3A4 due to the nature of the drug [64,65], which
may be caused by interactions with antihypertensive drugs [66,67]. However, DARO
has demonstrated a lower likelihood of drug–drug interactions than those of APA and
ENZA because DARO is structurally distinct from the two drugs [46,68]. Cardiotoxicity
is an important factor in the use of ENZA [69,70]. A previous meta-analysis showed
a significant increase in the relative risk of all-grade and high-grade cardiac toxicity in
patients receiving ENZA compared to that in patients receiving placebo [71]. In the
PROSPER trial, cardiotoxicity increased by approximately 2% with ENZA than with
placebo. APA had no cardiotoxic side effects apart from HTN, and DARO did not differ
from placebo in terms of cardiotoxicity.
The SPARTAN, PROSPER, and ARAMIS trials reported the occurrence of grade 3–4
AEs among 55.9%, 48%, and 26.3% of the intervention (APA, ENZA, and DARO) group
patients and 36.4%, 27%, and 26.3% of the placebo group patients, respectively.
In addition, as opposed to APA and ENZA, DARO did not have a higher rate of
drug discontinuation due to AEs than placebo did. According to a network meta-analysis,
DARO was found to be relatively superior to the two drugs in terms of safety.
As stated earlier, conclusions should not be drawn by comparing safety data from
different trials because differences exist in clinical trial design and included populations.
Ultimately, randomized head-to-head trials are required to compare safety profiles. Cur-
rently, the DaroAcT Trial (NCT04157088) is in progress and is expected to be completed
in 2022 [72]; it directly compares DARO and ENZA to assess differences in physical and
cognitive function.
4.4. Health-Related Quality of Life Outcomes
The ultimate treatment goal for nmCRPC is to maintain the patient’s QOL and delay
time to metastasis. Therefore, each of the three clinical trials evaluated QOL using a verified
questionnaire.
In the SPARTAN trial, health-related QOL (HR-QOL) was assessed using the Func-
tional Assessment of Cancer Therapy–Prostate (FACT-P) and European Quality of Life (EQ)
visual analog scale (VAS) [73,74]. After 29 months, for FACT-P, the APA and placebo groups
reported mean scores of −0.99 ± 0.98 and −3.29 ± 1.97, respectively. Additionally, for
EQ-VAS, the mean scores for the APA and placebo groups were 1.44 ± 0.87 and 0.26 ± 1.75,
respectively. There was no statistical difference, but the APA group had slightly better
QOL than did the placebo group. In the PROSPER trial, many comparisons were made
between placebo and ENZA groups regarding QOL. The FACT-P total score for the ENZA
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group was significantly better than that for the placebo group (HR 0.83; 95% CI 0.69–0.99;
p = 0.037). The mean score for the Brief Pain Inventory Short Form, which assesses pain
severity, was reported to be better in the ENZA group than in the placebo group (HR
0.75; 95% CI 0.57–0.97; p = 0.028). In addition, patients showed better bowel symptoms,
function, and urinary symptoms. The HR-QOL with DARO was reported based on prelim-
inary data [35]. DARO significantly delayed pain progression (HR 0.65; 95% CI 0.53–0.79;
p < 0.001) more than placebo did. Moreover, the delay in urinary symptoms was clinically
significant with DARO (HR, 0.64; 95% CI, 0.54–0.76; p < 0.01) than with placebo. A recent
study compared HR-QOL outcomes between APA and ENZA through matching-adjusted
indirect comparisons. They reported that, based on FACT-P scores, APA showed better
results than ENZA did [75]. However, since there is no direct comparison between the
three drugs yet, it is difficult to evaluate which drug facilitates superior QOL. All three
drugs may offer patients with nmCRPC a therapeutic option while maintaining QOL.
5. PSMA-PET Imaging in nmCRPC
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)
imaging can detect metastatic disease in a significant proportion of nmCRPC patients,
potentially leading to restaging. PSMA is overexpressed in prostate tumor cells. There are
research results on restaging in nmCRPC patients using PSMA-PET [76–79]. Frendler et al.
conducted a study using PSMA-PET by selecting patients similar to those included in the
SPARTAN, PROSPER, and ARAMIS trials [80]. It was a multicenter, retrospective study of
200 patients with nmCRPC who had a PSA level >2 ng/mL, PSADT ≤10 months, and/or
Gleason score ≥8. Conventional imaging showed absence of metastasis, but PSMA-PET
showed positive findings in 98% of the patients. In 44% of the patients, the metastasis
was confined to the pelvis with 24% of patients having metastasis in the prostate bed.
Furthermore, metastasis was found in 55% of the patients who developed it in the extra
pelvic nodes (39%), bone (24%), and visceral organs (6%). In another study, Fourquet et al.
included a total of 30 patients from relatively low-risk groups [81]. Among them, PSMA-
PET-positive findings were seen in 20 patients with PSA levels >2 ng/mL. In addition,
10 patients with PSA <2 ng/mL showed positive findings in 70%. PSMA-PET-positive
lesions were confined to the prostate bed in 7% of patients. In addition, 20% of the
patients had oligometastatic diseases with less than three lesions, and 63% of the patients
had polymetastatic disease. The current definition of nmCRPC is based on conventional
imaging modalities. However, given that PSMA-PET is a highly effective and universally
available diagnostic tool, we believe that the definition of nmCRPC and treatment plan
may change with the evolution of such diagnostic tools in the future. [82,83]
6. Conclusions
APA, ENZA, and DARO have excellent safety profiles for patients with nmCRPC. The
HR-QOL was preserved and prostate cancer-related symptoms were significantly delayed
in the intervention groups. Therefore, APA, ENZA, and DARO should be considered as
novel standard therapies for nmCRPC. However, the effects of these three drugs should be
compared through direct comparative studies in the future.
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